Covered recipient · General Payments record
LYNELL W KLASSEN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2021–2025
$67,628.11
- Reported across 73 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $21,600.00 | 16 |
| Food and Beverage | $18.54 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca UK Limited | $21,600.00 | 16 |
| Janssen Biotech, Inc. | $18.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202915016 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202927498 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202929920 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202958030 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202974452 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202986882 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/24/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202927574 | CMS |
| AstraZeneca UK Limited | $300.00 | 01/24/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202971760 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 02/14/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202951902 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 02/14/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202967624 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 03/13/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202914446 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 07/18/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202926902 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 07/18/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202953040 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 08/18/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202928878 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 09/04/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202943184 | CMS |
| AstraZeneca UK Limited | $2,400.00 | 09/18/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202916751 | CMS |
| Janssen Biotech, Inc. | $18.54 | 10/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1175144976 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.